Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer

被引:288
作者
Holst, Frederik
Stahl, Phillip R.
Ruiz, Christian
Hellwinkel, Olaf
Jehan, Zeenath
Wendland, Marc
Lebeau, Annette
Terracciano, Luigi
Al-Kuraya, Khawla
Jaenicke, Fritz
Sauter, Guido
Simon, Ronald [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, D-20246 Hamburg, Germany
[2] Univ Basel Hosp, Dept Pathol, CH-4031 Basel, Switzerland
[3] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20246 Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, D-20246 Hamburg, Germany
[5] King Faisal Specialist Hosp & Res Ctr, Riyadh 21211, Saudi Arabia
关键词
D O I
10.1038/ng2006
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Using an Affymetrix 10K SNP array to screen for gene copy number changes in breast cancer, we detected a single-gene amplification of the ESR1 gene, which encodes estrogen receptor alpha, at 6q25. A subsequent tissue microarray analysis of more than 2,000 clinical breast cancer samples showed ESR1 amplification in 20.6% of breast cancers. Ninety-nine percent of tumors with ESR1 amplification showed estrogen receptor protein overexpression, compared with 66.6% cancers without ESR1 amplification ( P < 0.0001). In 175 women who had received adjuvant tamoxifen monotherapy, survival was significantly longer for women with cancer with ESR1 amplification than for women with estrogen receptor - expressing cancers without ESR1 amplification ( P = 0.023). Notably, we also found ESR1 amplification in benign and precancerous breast diseases, suggesting that ESR1 amplification may be a common mechanism in proliferative breast disease and a very early genetic alteration in a large subset of breast cancers.
引用
收藏
页码:655 / 660
页数:6
相关论文
共 26 条
  • [1] Prognostic relevance of gene amplifications and coamplifications in breast cancer
    Al-Kuraya, K
    Schraml, P
    Torhorst, J
    Tapia, C
    Zaharieva, B
    Novotny, H
    Spichtin, H
    Maurer, R
    Mirlacher, M
    Köchli, O
    Zuber, M
    Dieterich, H
    Mross, F
    Wilber, K
    Simon, R
    Sauter, G
    [J]. CANCER RESEARCH, 2004, 64 (23) : 8534 - 8540
  • [2] ANDERSEN J, 1989, CANCER, V64, P1901, DOI 10.1002/1097-0142(19891101)64:9<1901::AID-CNCR2820640924>3.0.CO
  • [3] 2-W
  • [4] Courjal F, 1996, INT J CANCER, V69, P247
  • [5] Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab
    Dybdal, N
    Leiberman, G
    Anderson, S
    McCune, B
    Bajamonde, A
    Cohen, RL
    Mass, RD
    Sanders, C
    Press, MF
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) : 3 - 11
  • [6] FERLAY J, 2000, GLOBOCAN 2000 CANC I
  • [7] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    Harvey, JM
    Clark, GM
    Osborne, CK
    Allred, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1474 - 1481
  • [8] MAMMARY-CANCER - SELECTIVE ACTION OF THE ESTROGEN-RECEPTOR COMPLEX
    IP, M
    MILHOLLAND, RJ
    ROSEN, F
    KIM, U
    [J]. SCIENCE, 1979, 203 (4378) : 361 - 363
  • [9] KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355
  • [10] Estrogen receptor expression in benign breast epithelium and breast cancer risk
    Khan, SA
    Rogers, MAM
    Khurana, KK
    Meguid, MM
    Numann, PJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (01) : 37 - 42